Peptide-Fc Fusion Therapeutics: Applications and Challenges

Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges

Volumn , Issue , 2013, Pages 123-142

  Huang, Chichi ^a   Swanson, Ronald V ^b  

^a CENTOCOR INC   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Peptibody; Peptide drugs; Peptide Fc fusion; Peptide Fc fusion; Therapeutics, drugs

Indexed keywords

EID: 84886104600     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118354599.ch8     Document Type: Chapter

References (111)

1. Leader B, Baca QJ, Golan DE. (2008) Protein therapeutics: a summary and pharmacological classification. Nat. Rev. Drug Discov. 7, 21-39.
2. Lawrence S. (2007) Pipelines turn to biotech. Nat. Biotechnol. 25, 1342-1342.
3. Huggett B, Hodgson J, Lahteenmaki R. (2011) Public biotech 2010-the numbers. Nature Biotechnology 29, 585-591.
4. Biotech set to dominate drug industry growth on World Wide Web. 2009 Available at http://www.evaluatepharma.com/ U niversal/View.aspx?typ e1/4Story&id1/4188700 & se ctionID1/4&i sEPVa n ta ge1/4yes.
5. Huang, C. (2009). Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology. Curr Opin Biotechnol 20(6), 692-699
6. Kastin AJ. (2006) Handbook of Biologically Active Peptides. Academic Press, Amsterdam.
7. Adessi C, Soto C. (2002) Converting a peptide into a drug: strategies to improve stability and bioavailability. Curr. Med. Chem. 9, 963-978.
8. Gill TJ, 3rd, Gould HJ, Doty P. (1963) Role of optical isomers in determining the antigenicity of synthetic polypeptides. Nature 197, 746-747.
9. Tyndall JD, Nall T, Fairlie DP. (2005) Proteases universally recognize beta strands in their active sites. Chem. Rev. 105, 973-999.
10. Li P, Roller PP. (2002) Cyclization strategies in peptide derived drug design. Curr. Top. Med. Chem. 2, 325-341.
11. Blackwell HE, Sadowsky JD, Howard RJ, Sampson JN, Chao JA, Steinmetz WE, et al. (2001) Ring-closing metathesis of olefinic peptides: design, synthesis, and structural characterization of macrocyclic helical peptides. J. Org. Chem. 66, 5291-5302.
12. Verdine GL, Walensky LD. (2007) The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members. Clin. Cancer Res. 13, 7264-7270.
13. Henchey LK, Jochim AL, Arora PS, Henchey LK, Jochim AL, Arora PS. (2008) Contemporary strategies for the stabilization of peptides in the alpha-helical conformation. Curr. Opin. Chem. Biol. 12, 692-697.
14. Saladin PM, Zhang BD, Reichert JM, Saladin PM, Zhang BD, Reichert JM. (2009) Current trends in the clinical development of peptide therapeutics. Idrugs 12, 779-784.
15. Wilson AC, Meethal SV, Bowen RL, Atwood CS, Wilson AC, Meethal SV, et al. (2007) Leuprolide acetate: a drug of diverse clinical applications. Expert Opin. Investig. Drugs 16, 1851-1863.
16. Wingfield M, Healy DL. (1993) Endometriosis: medical therapy. Baillieres Clin. Obstet. Gynaecol. 7, 813-838.
17. Lamberts SW, Reubi JC, Krenning EP. (1992) Somatostatin analogs in the treatment of acromegaly. Endocrinol. Metab. Clin. North Am. 21, 737-752.
18. Peeters M, Van den Brande J, Francque S. (2010) Diarrhea and the rationale to use Sandostatin. Acta Gastroenterol. Belg. 73, 25-36.
19. Blick SK, Dhillon S, Keam SJ, Blick SKA, Dhillon S, Keam SJ. (2008) Teriparatide: a review of its use in osteoporosis. Drugs 68, 2709-2737.
20. Overington JP, Al-Lazikani B, Hopkins AL. (2006) How many drug targets are there? Nat. Rev. Drug Discov. 5, 4.
21. Cochran AG. (2000) Antagonists of protein-protein interactions. Chem. Biol. 7, R85-R94.
22. Bailon P, Won CY, Bailon P, Won CY. (2009) PEG-modified biopharmaceuticals. Expert Opin. Drug Deliv. 6, 1-16.
23. Roberts MJ, Bentley MD, Harris JM. (2002) Chemistry for peptide and protein PEGylation. Adv. Drug Deliv. Rev. 54, 459-476.
24. Werle M, Bernkop-Schnurch A. (2006) Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids 30, 351-367.
25. Stead RB, Lambert J, Wessels D, Iwashita JS, Leuther KK, Woodburn KW, et al. (2006) Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood 108, 1830-1834.
26. McGregor DP. (2008) Discovering and improving novel peptide therapeutics. Curr. Opin. Pharmacol. 8, 616-619.
27. Lee SH, Lee S, Youn YS, Na DH, Chae SY, Byun Y, et al. (2005) Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1. Bioconjug. Chem. 16, 377-382.
28. St Onge EL, Miller SA. (2010) Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes. Expert Opin. Biol. Ther. 10, 801-806.
29. Nelson DR, Benhamou Y, Chuang WL, Lawitz EJ, Rodriguez- Torres M, Flisiak R, et al. (2010) Albinterferon Alfa-2b was not inferior to pegylated interferon- in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3. Gastroenterology 139, 1267-1276.
30. Halpern W, Riccobene TA, Agostini H, Baker K, Stolow D, Gu ML, et al. (2002) Albugranin, a recombinant human granulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys. Pharm. Res. 19, 1720-1729.
31. Duttaroy A, Kanakaraj P, Osborn BL, Schneider H, Pickeral OK, Chen C, et al. (2005) Development of a long-acting insulin analog using albumin fusion technology. Diabetes 54, 251-258.
32. Wang W, Ou Y, Shi Y. (2004) AlbuBNP, a recombinant B-type natriuretic peptide and human serum albumin fusion hormone, as a long-term therapy of congestive heart failure. Pharm. Res. 21, 2105-2111.
33. Abraham S, Guo F, Li LS, Rader C, Liu C, Barbas CF, 3rd, et al. (2007) Synthesis of the next-generation therapeutic antibodies that combine cell targeting and antibodycatalyzed prodrug activation. Proc. Natl. Acad. Sci. USA 104, 5584-5589.
34. Lencer WI, Blumberg RS. (2005) A passionate kiss, then run: exocytosis and recycling of IgG by FcRn. Trends Cell Biol. 15, 5-9.
35. Roopenian DC, Akilesh S. (2007) FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7, 715-725.
36. Goldenberg MM. (1999) Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clin. Ther. 21, 75-87; discussion 71-72.
37. Capon DJ, Chamow SM, Mordenti J, Marsters SA, Gregory T, Mitsuya H, et al. (1989) Designing CD4 immunoadhesins for AIDS therapy. Nature 337, 525-531.
38. Byrn RA, Mordenti J, Lucas C, Smith D, Marsters SA, Johnson JS, et al. (1990) Biological properties of a CD4 immunoadhesin. Nature 344, 667-670.
39. Chamow SM, DuliegeAM, Ammann A, Kahn JO, Allen JD, Eichberg JW, et al. (1992) CD4 immunoadhesins in anti- HIV therapy: new developments. Int. J. Cancer Suppl. 7, 69-72.
40. Ashkenazi A, Capon DJ, Ward RH. (1993) Immunoadhesins. Int. Rev. Immunol. 10, 219-227.
41. Low SC, Nunes SL, Bitonti AJ, Dumont JA. (2005) Oral and pulmonary delivery of FSH-Fc fusion proteins via neonatal Fc receptor-mediated transcytosis. Hum. Reprod. 20, 1805-1813.
42. Bitonti AJ, Dumont JA, Low SC, Peters RT, Kropp KE, Palombella VJ, et al. (2004) Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc. Natl. Acad. Sci. USA 101, 9763-9768.
43. Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, Kavanaugh A, et al. (2008) Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebocontrolled studies. Arthritis Rheum. 58, 2443-2452.
44. Oliner J, Min H, Leal J, Yu D, Rao S, You E, et al. (2004) Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 6, 507-516.
45. Karlan BY, Oza AM, Hansen VL, Richardson GE, Provencher DM, Ghatage P, et al. (2010) Randomized, doubleblind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients (pts) with recurrent ovarian carcinoma [Abstract 5000]. J. Clin. Oncol. 28.
46. Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM, et al. (2009) Safety, pharmacokinetics, and antitumor activity ofAMG386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J. Clin. Oncol. 27, 3557-3565.
47. Umpierrez GE,BlevinsT,RosenstockJ,ChengC,AndersonJH, Bastyr EJ, 3rd. (2011) The effects of LY2189265, a long-acting glucagon-like peptide-1 analog, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: theEGOstudy. Diabetes Obes. Metab.13, 418-425.
48. Amersi F, Farmer DG, Shaw GD, Kato H, Coito AJ, Kaldas F, et al. (2002) P-selectin glycoprotein ligand-1 (rPSGL-Ig)- mediated blockade of CD62 selectin molecules protects rat steatotic liver grafts from ischemia/reperfusion injury. Am. J. Transplant. 2, 600-608.
49. Ruckle J, Jacobs M, Kramer W, Pearsall AE, Kumar R, Underwood KW, et al. (2009) Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J. Bone Miner. Res. 24, 744-752.
50. Lachey JL, Wachtman LM, Mansfield KG, Persall RS, Lane JH, Seehra JS. (2008) Treatment with a soluble activin receptor type IIb results increased muscle mass in marmosets [Abstract]. New Dir. Biol. Dis. Skelet. Muscle.
51. Long L, Brennan T, Zanghi J, Palencia S, Cheung R, Aguirre M, et al. (2009) Preclinical antitumor efficacy of FP-1039, a soluble FGF receptor 1:Fc conjugate, as a single agent or in combination with anti-cancer drugs [Abstract]. AACR 100th Annual Meeting.
52. Dumont JA, Low SC, Peters RT, Bitonti AJ. (2006) Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics. BioDrugs 20, 151-160.
53. Peters RT, Low SC, Kamphaus GD, Dumont JA, Amari JV, Lu Q, Zarbis-Papastoitsis G, Reidy TJ, Merricks EP, Nichols TC, et al.: Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood 2010, 115, 2057-2064.
54. Jazayeri JA, Carroll GJ. (2008) Fc-based cytokines: prospects for engineering superior therapeutics. BioDrugs 22, 11-26.
55. Ashkenazi A, Chamow SM. (1997) Immunoadhesins as research tools and therapeutic agents. Curr. Opin. Immunol. 9, 195-200.
56. Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, et al. (1993) Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol. 151, 1548-1561.
57. Ducharme E, Weinberg JM. (2008) Etanercept. Expert Opin. Biol. Ther. 8, 491-502.
58. Miller GT, Hochman PS, Meier W, Tizard R, Bixler SA, Rosa MD, et al. (1993) Specific interaction of lymphocyte function- associated antigen 3 with CD2 can inhibit T cell responses. J. Exp. Med. 178, 211-222.
59. Burton DR, Woof JM. (1992) Human antibody effector function. Adv. Immunol. 51, 1-84.
60. Tao MH, Smith RI, Morrison SL. (1993) Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J. Exp. Med. 178, 661-667.
61. Strohl WR. Non-immunostimulatory antibody and compositions containing the same. US patent application 2007/0148167 A1, 2007.
62. De Groot AS, Scott DW. (2007) Immunogenicity of protein therapeutics. Trends Immunol. 28, 482-490.
63. Marshall SA, Lazar GA, Chirino AJ, Desjarlais JR. (2003) Rational design and engineering of therapeutic proteins. Drug Discov. Today 8, 212-221.
64. Emamaullee J, Toso C, Merani S, Shapiro AM. (2009) Costimulatory blockade with belatacept in clinical and experimental transplantation-a review. Expert Opin. Biol. Ther. 9, 789-796.
65. Larsen CP, Pearson TC, Adams AB, Tso P, Shirasugi N, Strobertm E, et al. (2005) Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am. J. Transplant. 5, 443-453.
66. Bracewell C, Isaacs JD, Emery P, Ng WF. (2009) Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis. Expert Opin. Biol. Ther. 9, 909-919.
67. Gross JA, Dillon SR, Mudri S, Johnston J, Littau A, Roque R, et al. (2001) TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease impaired B cell maturation in mice lacking BLyS. Immunity 15, 289-302.
68. Vugmeyster Y, Seshasayee D, Chang W, Storn A, Howell K, Sa S, et al. (2006) A soluble BAFF antagonist, BR3-Fc, decreases peripheral blood B cells and lymphoid tissue marginal zone and follicular B cells in cynomolgus monkeys. Am. J. Pathol. 168, 476-489.
69. Lundquist L. (2007) Abatacept: a novel therapy approved for the treatment of patients with rheumatoid arthritis. Adv. Ther. 24, 333-345.
70. Farmer DG, Shen XD, Amersi F, Anselmo D, Ma JP, Ke B, et al. (2005) CD62 blockade with P-Selectin glycoprotein ligand-immunoglobulin fusion protein reduces ischemiareperfusion injury after rat intestinal transplantation. Transplantation 79, 44-51.
71. Peppel K, Crawford D, Beutler B. (1991) A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J. Exp. Med. 174, 1483-1489.
72. Strober BE, Menon K. (2007) Alefacept for the treatment of psoriasis and other dermatologic diseases. Dermatol. Ther. 20, 270-276.
73. Korhonen R, Moilanen E. (2009) Abatacept, a novel CD80/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis. Basic Clin. Pharmacol. Toxicol. 104, 276-284.
74. Davis PM, Abraham R, Xu L, Nadler SG, Suchard SJ. (2007) Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity. J. Rheumatol. 34, 2204-2210.
75. Economides AN, Carpenter LR, Rudge JS,Wong V, Koehler- Stec EM, Hartnett C, et al. (2003) Cytokine traps: multicomponent, high-affinity blockers of cytokine action. Nat. Med. 9, 47-52.
76. Bruggemann M,Williams GT, Bindon CI, Clark MR,Walker MR, Jefferis R, et al. (1987) Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J. Exp. Med. 166, 1351-1361.
77. Jefferis R. (2007) Antibody therapeutics: isotype and glycoform selection. Expert Opin. Biol. Ther. 7, 1401-1413.
78. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. (2007) Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat. Biotechnol. 25, 1256-1264.
79. Ashkenazi A, Chamow SM. (1995) Immunoadhesins: an alternative to human monoclonal antibodies. Methods 8, 104.
80. International Nonproprietary Names for Pharmaceutical Substances (INN). In WHO Drug Information. (2009). vol 23.
81. Frampton JE, Lyseng-Williamson KA. (2009) Romiplostim. Drugs 69, 307-317.
82. Nichol JL. (2006) AMG 531: an investigational thrombopoiesis- stimulating peptibody. Pediatr. Blood Cancer 47, 723-725.
83. Broudy VC, Lin NL, Broudy VC, Lin NL. (2004) AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine 25, 52-60.
84. Newland A. (2009) Romiplostim: a breakthrough treatment for the management of immune thrombocytopenic purpura. Eur. J. Haematol. Suppl. S.71, 20-25.
85. Stohl W, Looney RJ. (2006) B cell depletion therapy in systemic rheumatic diseases: different strokes for different folks? Clin. Immunol. 121, 1-12.
86. Kuchimanchi K, Narayanan A, KrzyzanskiW,Wild S, Ferbas J,Wang T, et al. Pharmacokinetics and Pharmacodynamics of a Novel Polypeptide Fusion Protein- AMG 623 in: Cynomolgus Monkeys [Abstract]. AAPS aaps2007-003196.
87. Glaesner W, Vick AM, Millican R, Ellis B, Tschang SH, Tian Y, et al. (2010) Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes/Metab. Res. Rev. 26, 287-296.
88. Barrington P, Chien JY, Tibaldi F, Showalter HD, Schneck K, Ellis B. (2011) LY2189265, a long-acting glucagon likepeptide-analog, demonstrated dose-dependent insulin secretion in healthy subjects. Diabetes Obes. Metab. 13, 434-438.
89. Barrington P, Chien JY, Showalter HD, Schneck K, Cui S, Tibaldi F, et al. (2011) A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analog, in patients with type 2 diabetes. Diabetes Obes. Metab. 13, 426-433.
90. Wrighton NC, Farrell FX, Chang R, Kashyap AK, Barbone FP, Mulcahy LS, et al. (1996) Small peptides as potent mimetics of the protein hormone erythropoietin. Science 273, 458-464.
91. Bouman-Thio E, Franson K, Miller B, Getsy J, Cohen A, Bai SA, et al. (2008) A phase I, single and fractionated, ascending-dose study evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of an erythropoietin mimetic antibody fusion protein (CNTO 528) in healthy male subjects. J. Clin. Pharmacol. 48, 1197-1207.
92. Bugelski PJ, Capocasale RJ, Makropoulos D, Marshall D, Fisher PW, Lu J, et al. (2008) CNTO 530: molecular pharmacology in human UT-7EPO cells and pharmacokinetics and pharmacodynamics in mice. J. Biotechnol. 134, 171-180.
93. Picha KM, Cunningham MR, Drucker DJ, Mathur A, Ort T, Scully M, et al. (2008) Protein engineering strategies for sustained glucagon-like peptide-1 receptor-dependent control of glucose homeostasis. Diabetes 57, 1926-1934.
94. Johnson DL, Farrell FX, Barbone FP, McMahon FJ, Tullai J, Hoey K, et al. (1998) Identification of a 13 amino acid peptide mimetic of erythropoietin and description of amino acids critical for the mimetic activity of EMP1. Biochemistry 37, 3699-3710.
95. Bugelski, P.J., Makropoulos, D. Spinka-Doms, T. Eirikis, E. Volk, A. Jiao, Q. Huang, C. (2011) Differential Effects of Long-lived Erythropoietin Receptor Agonists in Rats. Pharmaceutica Analytica Acta 2:7.
96. Hutchins JT, Kull FC, Jr, Bynum J, Knick VC, Thurmond LM, Ray P. (1995) Improved biodistribution, tumor targeting, and reduced immunogenicity in mice with a gamma 4 variant of Campath-1H. Proc. Natl. Acad. Sci. USA 92, 11980- 11984.
97. Hermeling S, Crommelin DJ, Schellekens H, Jiskoot W. (2004) Structure-immunogenicity relationships of therapeutic proteins. Pharm. Res. 21, 897-903.
98. Cromwell ME, Hilario E, Jacobson F. (2006) Protein aggregation and bioprocessing. AAPS J. 8, E572-579.
99. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99, 754-758.
100. Lazar GA, DangW, Karki S, Vafa O, Peng JS, Hyun L, et al. (2006) Engineered antibody Fc variants with enhanced effector function. Proc. Natl. Acad. Sci. USA 103, 4005- 4010.
101. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, et al. (2002) Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277, 26733-26740.
102. Crispin M, Bowden TA, Coles CH, Harlos K, Aricescu AR, Harvey DJ, et al. (2009) Carbohydrate and domain architecture of an immature antibody glycoform exhibiting enhanced effector functions. J. Mol. Biol. 387, 1061-1066.
103. Raju TS. (2008) Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr. Opin. Immunol. 20, 471-478.
104. Xu D, Alegre ML, Varga SS, Rothermel AL, Collins AM, Pulito VL, et al. (2000) In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol. 200, 16-26.
105. Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, et al. (2009) Treatment of patients with new onset type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin. Immunol. 132, 166-173.
106. Madsbad S, Kielgast U, Asmar M, Deacon C, Torekov SS, Holst JJ. (2011) An overview of once-weekly GLP-1 receptor agonists-available efficacy and safety data and perspectives for the future. Diabetes Obes. Metab. 60, 1599-1607.
107. Chu QS. (2009) Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. Expert Opin. Biol. Ther. 9, 263-271.
108. Mack GS. (2008) CD20 blockers eye crowded rheumatology market. Nat. Biotechnol. 26, 1053-1054.
109. Hayden-Ledbetter MS, Cerveny CG, Espling E, Brady WA, Grosmaire LS, Tan P, et al. (2009) CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells. Clin. Cancer Res. 15, 2739-2746.
110. Burge DJ, Bookbinder SA, Kivitz AJ, Fleischmann RM, Shu C, Bannink J. (2008) Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: a Phase I, open-label, dose-escalation clinical study. Clin. Ther. 30, 1806-1816.
111. Saerens D, Ghassabeh GH, Muyldermans S. (2008) Singledomain antibodies as building blocks for novel therapeutics. Curr. Opin. Pharmacol. 8, 600-608.